Please check out the results (in press in Kidney International) of our latest study where we develop a urinary peptide classifier based on molecular signatures similar in mice and humans that will, we believe, significantly speed up preclinical drug research.
A major issue in drug research is that many potential drugs work fine in animal models but do significantly less well in humans (or not work at all). To improve on the validity of preclinical observations we have developped a non-invasive multimolecular humanized readout in mice based on molecular signatures similar in mice and humans. Such read-out will allow to find out at an early stage (eg preclinical) whether a new drug is likely to work in humans as well.
We have applied our approach to chronic kidney disease in type 2 diabetes, a major non-communicable disease. A model based on a panel of 21 urinary peptides, similar in mice and humans, predicted the response to disease (eg chronic kidney disease) and treatment with inhibitors of the renin-angiotensin system (standard of care treatment) in mice and man.